SELLAS Life Sciences Group (SLS) Stock Forecast: StockMap's 2-Week Call
SLS stock forecast: StockMap's model leans Outperform on SELLAS Life Sciences Group for the two weeks after the Nov 18 close, toward SLS doing better than the growth index. It is a lean inside the no-call band, not a call, and not a price target. Too few two-week windows graded to judge yet.
SELLAS Life Sciences Group last closed at $17.95, -6.27% on the session.
Against the IVW growth benchmark the position is -6.29% over the forecast window.
SELLAS Life Sciences Group's market cap is $3.66B as of November 18, 2026.
Leans up ↗: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is 39 (too close to call).
Where SLS sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 11 bullish and 4 bearish.
Agreement across those insights is 73%.
4 daily calls for SLS so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks SELLAS Life Sciences Group in the 21st percentile on return on equity, where 100 is best.
SELLAS Life Sciences Group is classified under Health Care / Biotechnology.
StockMap tracks SELLAS Life Sciences Group as the 58th largest of the 393 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 195 Moderate Underperform, 141 Neutral, 42 Strong Underperform and 15 Moderate Outperform.
On that composite SELLAS Life Sciences Group ranks 5th of 393 in the group, against a group median of -0.27.